Collagen Solutions assembles scientific advisory board

19th Jan 2017 09:37

(ShareCast News) - Developer and manufacturer of medical grade collagen components, Collagen Solutions, announced the creation of a new scientific advisory board on Thursday, that will advise the company on opportunities in regenerative medicine.The AIM-traded company said the three appointees are Andrew Lynn, William Walsh and Tom Buckland.It said Dr Lynn is a successful entrepreneur with experience in early-stage life-sciences and technology companies.He is currently CEO of Fluid Analytics, and was also the founder of Orthomimetics, which developed ChondroMimetic-based on the work for his PhD thesis at the University of Cambridge.He has acted as a close adviser to the company on the development programme for ChondroMimetic following the acquisition of Orthomimetics assets in September 2015. Professor Walsh reportedly has more than 27 years of academic and industry-related research experience in orthopaedics and other surgical fields.He is currently a full professor at the Prince of Wales Clinical School at the University of New South Wales, Australia and Director of the Surgical and Orthopaedic Research Laboratories.Professor Walsh's research interests are in understanding the molecular interactions at the interface between implanted materials and the connective tissues of the body, as it relates to orthopaedic, plastic and reconstructive and vascular surgery.Collagen Solutions' board said he has extensive practical experience of working with the novel collagen-based products that the company has developed.Finally, Dr Buckland was a co-founder of ApaTech, research and development director with Baxter, and managing director of NuVasive UK.The board said he has more than 15 years of experience in medical device product development, manufacture, regulatory approval, intellectual property management and commercialisation.Dr Buckland holds several non-executive director positions with start-up companies in the orthopaedic space, in addition to his role as entrepreneur-in-residence within the technology transfer group at Imperial Innovations, where he is focused on managing the orthopaedic portfolio and selected medical technologies."We have assembled a highly experienced and dynamic scientific advisory board with a combination of significant industry backgrounds and complementary technical and scientific knowledge within the field of regenerative medicine," said CEO Jamal Rushdy."In addition to providing advice and direction on our current development projects and core business, the SAB will help us to assess future market directions and to guide our activities towards the development of both commercially and clinically relevant, next generation products."